RxDoctor Payments Data

Lakshmana Pendyala, MD

Cardiovascular Disease · Jeffersonville, INNPI 1144217746

Payments from drug & device makers

$33,164in general payments, 2019–2025

Across 463 payments — averaging $71.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$23K
  • Boston Scientific$2K
  • Johnson & Johnson$944
  • Abbott$869
  • Amgen$686
  • E.r. Squibb & Sons, L.L.C.$611
  • plus $6K from 36 others

What the payments were for

  • Speaking & faculty fees$20,40062%
  • Food & beverage$12,72038%
  • Education$430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,164 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$283,877
Medicare patients
1,343
Services billed
4,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban465$431,972
BrilintaTicagrelor86$63,448
EntrestoSacubitril/Valsartan70$60,786
XareltoRivaroxaban38$56,691
FarxigaDapagliflozin Propanediol49$43,125
JardianceEmpagliflozin22$33,002
Ranolazine ErRanolazine225$30,149
Repatha SyringeEvolocumab38$29,735
Repatha SureclickEvolocumab47$29,230
Praluent PenAlirocumab31$15,949
VascepaIcosapent Ethyl23$8,852
Midodrine Hcl33$8,533
Metoprolol Succinate537$4,915
Droxidopa12$4,537
Prasugrel Hcl14$4,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$478$431,972465 claims
AstraZenecaBrilinta, Farxiga$22,512$106,573135 claims
NovartisEntresto$521$60,78670 claims
Johnson & JohnsonXarelto$944$56,69138 claims
Boehringer IngelheimJardiance$134$33,00222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →